Literature DB >> 35185292

Establishment of serum-free adapted Chinese hamster ovary cells with double knockout of GDP-mannose-4,6-dehydratase and GDP-fucose transporter.

Ryo Misaki1, Masashi Iwasaki1, Hiroki Takechi1, Noriko Yamano-Adachi2, Takao Ohashi1, Hiroyuki Kajiura1, Kazuhito Fujiyama1,3.   

Abstract

Although antibodies have attracted attention as next-generation biopharmaceuticals, the costs of purifying the products and of arranging the environment for cell cultivation are high. Therefore, there is a need to increase antibody efficacy and improve product quality as much as possible. Since antibodies are glycoproteins, their glycan structures have been found to affect the function of antibodies. Especially, afucosylation of the N-linked glycan in the Fc region is known to significantly increase antibody-dependent cellular cytotoxicity. In this study, we established a double-mutant ΔGMDΔGFT in which GDP-mannose 4,6-dehydratase and GDP-fucose transporter were knocked out in Chinese hamster ovary cells, a platform for biopharmaceutical protein production. By adapting ΔGMDΔGFT cells to serum-free medium and constructing suspension-cultured cells, we established host CHO cells with no detected fucosylated glycans and succeeded in production of afucosylated antibodies. We also demonstrated that, in culture in the presence of serum, fucosylation occurs due to contamination from serum components. Furthermore, we found that afucosylation of glycans does not affect cell growth after adaptation to serum-free medium as compared to wild-type CHO cells growth and does not significantly affect the expression levels of other endogenous fucose metabolism-related enzyme genes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10616-021-00501-3.
© The Author(s), under exclusive licence to Springer Nature B.V. 2021.

Entities:  

Keywords:  Chinese hamster ovary cell; Fucosylation; GDP-fucose; N-glycan; Serum-free medium adaptation

Year:  2022        PMID: 35185292      PMCID: PMC8817005          DOI: 10.1007/s10616-021-00501-3

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  36 in total

1.  Decrease in antithrombin III fucosylation by expressing GDP-fucose transporter siRNA in Chinese hamster ovary cells.

Authors:  Takeshi Omasa; Ryo Tanaka; Tomohiro Doi; Masayuki Ando; Yuka Kitamoto; Kohsuke Honda; Michimasa Kishimoto; Hisao Ohtake
Journal:  J Biosci Bioeng       Date:  2008-08       Impact factor: 2.894

2.  Biopharmaceutical benchmarks 2018.

Authors:  Gary Walsh
Journal:  Nat Biotechnol       Date:  2018-12-06       Impact factor: 54.908

3.  What's fueling the biotech engine-2012 to 2013.

Authors:  Rob Saurabh Aggarwal
Journal:  Nat Biotechnol       Date:  2014-01       Impact factor: 54.908

4.  Highly efficient deletion of FUT8 in CHO cell lines using zinc-finger nucleases yields cells that produce completely nonfucosylated antibodies.

Authors:  Laetitia Malphettes; Yevgeniy Freyvert; Jennifer Chang; Pei-Qi Liu; Edmond Chan; Jeffrey C Miller; Zhe Zhou; Thu Nguyen; Christina Tsai; Andrew W Snowden; Trevor N Collingwood; Philip D Gregory; Gregory J Cost
Journal:  Biotechnol Bioeng       Date:  2010-08-01       Impact factor: 4.530

5.  Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.

Authors:  Shigeru Iida; Hirofumi Misaka; Miho Inoue; Mami Shibata; Ryosuke Nakano; Naoko Yamane-Ohnuki; Masako Wakitani; Keiichi Yano; Kenya Shitara; Mitsuo Satoh
Journal:  Clin Cancer Res       Date:  2006-05-01       Impact factor: 12.531

6.  FX knockout CHO hosts can express desired ratios of fucosylated or afucosylated antibodies with high titers and comparable product quality.

Authors:  Salina Louie; Benjamin Haley; Brett Marshall; Amy Heidersbach; Mandy Yim; Martina Brozynski; Danming Tang; Cynthia Lam; Bronislawa Petryniak; David Shaw; Jeongsup Shim; Aaron Miller; John B Lowe; Brad Snedecor; Shahram Misaghi
Journal:  Biotechnol Bioeng       Date:  2016-10-04       Impact factor: 4.530

7.  Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity.

Authors:  Naoko Yamane-Ohnuki; Satoko Kinoshita; Miho Inoue-Urakubo; Machi Kusunoki; Shigeru Iida; Ryosuke Nakano; Masako Wakitani; Rinpei Niwa; Mikiko Sakurada; Kazuhisa Uchida; Kenya Shitara; Mitsuo Satoh
Journal:  Biotechnol Bioeng       Date:  2004-09-05       Impact factor: 4.530

8.  CHO-gmt5, a novel CHO glycosylation mutant for producing afucosylated and asialylated recombinant antibodies.

Authors:  Ryan Haryadi; Peiqing Zhang; Kah Fai Chan; Zhiwei Song
Journal:  Bioengineered       Date:  2012-03-01       Impact factor: 3.269

9.  Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma.

Authors:  Rinpei Niwa; Emi Shoji-Hosaka; Mikiko Sakurada; Toyohide Shinkawa; Kazuhisa Uchida; Kazuyasu Nakamura; Kouji Matsushima; Ryuzo Ueda; Nobuo Hanai; Kenya Shitara
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

Review 10.  Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications.

Authors:  Anshu Kuriakose; Narendra Chirmule; Pradip Nair
Journal:  J Immunol Res       Date:  2016-06-29       Impact factor: 4.818

View more
  1 in total

Review 1.  Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies.

Authors:  Josée Golay; Alain E Andrea; Irene Cattaneo
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.